Neoantigen Cancer Vaccine  Market Report

Global Neoantigen Cancer Vaccine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：148
  • REPORT CODE：GMM853373
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Neoantigen Cancer Vaccine market report explains the definition, types, applications, major countries, and major players of the Neoantigen Cancer Vaccine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Vaccibody

    • Brightpath Biotherapeutics

    • Agenus

    • Merck

    • OSE Immunotherapeutics

    • Advaxis

    • Medigene

    • Genocea

    • Gritstone Oncology

    • Nouscom

    • Medimmune

    • Roche

    • Geneos Therapeutics

    • Neon Therapeutics

    By Type:

    • Personalized Vaccine

    • Off-the-shelf Neovaccines

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Neoantigen Cancer Vaccine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Neoantigen Cancer Vaccine Outlook to 2028- Original Forecasts

    • 2.2 Neoantigen Cancer Vaccine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Neoantigen Cancer Vaccine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Neoantigen Cancer Vaccine Market- Recent Developments

    • 6.1 Neoantigen Cancer Vaccine Market News and Developments

    • 6.2 Neoantigen Cancer Vaccine Market Deals Landscape

    7 Neoantigen Cancer Vaccine Raw Materials and Cost Structure Analysis

    • 7.1 Neoantigen Cancer Vaccine Key Raw Materials

    • 7.2 Neoantigen Cancer Vaccine Price Trend of Key Raw Materials

    • 7.3 Neoantigen Cancer Vaccine Key Suppliers of Raw Materials

    • 7.4 Neoantigen Cancer Vaccine Market Concentration Rate of Raw Materials

    • 7.5 Neoantigen Cancer Vaccine Cost Structure Analysis

      • 7.5.1 Neoantigen Cancer Vaccine Raw Materials Analysis

      • 7.5.2 Neoantigen Cancer Vaccine Labor Cost Analysis

      • 7.5.3 Neoantigen Cancer Vaccine Manufacturing Expenses Analysis

    8 Global Neoantigen Cancer Vaccine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Neoantigen Cancer Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Neoantigen Cancer Vaccine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Neoantigen Cancer Vaccine Market Outlook by Types and Applications to 2022

    • 9.1 Global Neoantigen Cancer Vaccine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Personalized Vaccine Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Off-the-shelf Neovaccines Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neoantigen Cancer Vaccine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Neoantigen Cancer Vaccine Market Analysis and Outlook till 2022

    • 10.1 Global Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.2.2 Canada Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.2.3 Mexico Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.2 UK Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.3 Spain Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.4 Belgium Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.5 France Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.6 Italy Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.7 Denmark Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.8 Finland Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.9 Norway Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.10 Sweden Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.11 Poland Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.12 Russia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.3.13 Turkey Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.2 Japan Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.3 India Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.4 South Korea Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.5 Pakistan Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.6 Bangladesh Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.7 Indonesia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.8 Thailand Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.9 Singapore Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.10 Malaysia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.11 Philippines Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.4.12 Vietnam Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.2 Colombia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.3 Chile Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.4 Argentina Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.5 Venezuela Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.6 Peru Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.5.8 Ecuador Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.6.2 Kuwait Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.6.3 Oman Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.6.4 Qatar Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.7.2 South Africa Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.7.3 Egypt Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.7.4 Algeria Neoantigen Cancer Vaccine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Neoantigen Cancer Vaccine Consumption (2017-2022)

      • 10.8.2 New Zealand Neoantigen Cancer Vaccine Consumption (2017-2022)

    11 Global Neoantigen Cancer Vaccine Competitive Analysis

    • 11.1 Vaccibody

      • 11.1.1 Vaccibody Company Details

      • 11.1.2 Vaccibody Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Vaccibody Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.1.4 Vaccibody Neoantigen Cancer Vaccine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Brightpath Biotherapeutics

      • 11.2.1 Brightpath Biotherapeutics Company Details

      • 11.2.2 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.2.4 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Agenus

      • 11.3.1 Agenus Company Details

      • 11.3.2 Agenus Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Agenus Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.3.4 Agenus Neoantigen Cancer Vaccine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Merck

      • 11.4.1 Merck Company Details

      • 11.4.2 Merck Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Merck Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.4.4 Merck Neoantigen Cancer Vaccine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 OSE Immunotherapeutics

      • 11.5.1 OSE Immunotherapeutics Company Details

      • 11.5.2 OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.5.4 OSE Immunotherapeutics Neoantigen Cancer Vaccine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Advaxis

      • 11.6.1 Advaxis Company Details

      • 11.6.2 Advaxis Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Advaxis Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.6.4 Advaxis Neoantigen Cancer Vaccine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Medigene

      • 11.7.1 Medigene Company Details

      • 11.7.2 Medigene Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Medigene Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.7.4 Medigene Neoantigen Cancer Vaccine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Genocea

      • 11.8.1 Genocea Company Details

      • 11.8.2 Genocea Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Genocea Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.8.4 Genocea Neoantigen Cancer Vaccine Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Gritstone Oncology

      • 11.9.1 Gritstone Oncology Company Details

      • 11.9.2 Gritstone Oncology Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Gritstone Oncology Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.9.4 Gritstone Oncology Neoantigen Cancer Vaccine Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Nouscom

      • 11.10.1 Nouscom Company Details

      • 11.10.2 Nouscom Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Nouscom Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.10.4 Nouscom Neoantigen Cancer Vaccine Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Medimmune

      • 11.11.1 Medimmune Company Details

      • 11.11.2 Medimmune Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Medimmune Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.11.4 Medimmune Neoantigen Cancer Vaccine Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Roche

      • 11.12.1 Roche Company Details

      • 11.12.2 Roche Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Roche Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.12.4 Roche Neoantigen Cancer Vaccine Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 Geneos Therapeutics

      • 11.13.1 Geneos Therapeutics Company Details

      • 11.13.2 Geneos Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 Geneos Therapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.13.4 Geneos Therapeutics Neoantigen Cancer Vaccine Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    • 11.14 Neon Therapeutics

      • 11.14.1 Neon Therapeutics Company Details

      • 11.14.2 Neon Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.14.3 Neon Therapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

      • 11.14.4 Neon Therapeutics Neoantigen Cancer Vaccine Product Portfolio

      • 11.14.5 Recent Research and Development Strategies

    12 Global Neoantigen Cancer Vaccine Market Outlook by Types and Applications to 2028

    • 12.1 Global Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Personalized Vaccine Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Off-the-shelf Neovaccines Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Neoantigen Cancer Vaccine Market Analysis and Outlook to 2028

    • 13.1 Global Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.2 UK Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.5 France Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.3 India Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Neoantigen Cancer Vaccine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Neoantigen Cancer Vaccine

    • Figure of Neoantigen Cancer Vaccine Picture

    • Table Global Neoantigen Cancer Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Neoantigen Cancer Vaccine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Personalized Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Global Off-the-shelf Neovaccines Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Table North America Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure United States Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Canada Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table Europe Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure Germany Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure UK Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Spain Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure France Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Italy Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Finland Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Norway Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Poland Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Russia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table APAC Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure China Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Japan Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure India Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table South America Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure Brazil Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Chile Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Peru Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table GCC Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure Bahrain Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Oman Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table Africa Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure Nigeria Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table Oceania Neoantigen Cancer Vaccine Consumption by Country (2017-2022)

    • Figure Australia Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Neoantigen Cancer Vaccine Consumption and Growth Rate (2017-2022)

    • Table Vaccibody Company Details

    • Table Vaccibody Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vaccibody Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Vaccibody Neoantigen Cancer Vaccine Product Portfolio

    • Table Brightpath Biotherapeutics Company Details

    • Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product Portfolio

    • Table Agenus Company Details

    • Table Agenus Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Agenus Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Agenus Neoantigen Cancer Vaccine Product Portfolio

    • Table Merck Company Details

    • Table Merck Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Merck Neoantigen Cancer Vaccine Product Portfolio

    • Table OSE Immunotherapeutics Company Details

    • Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table OSE Immunotherapeutics Neoantigen Cancer Vaccine Product Portfolio

    • Table Advaxis Company Details

    • Table Advaxis Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Advaxis Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Advaxis Neoantigen Cancer Vaccine Product Portfolio

    • Table Medigene Company Details

    • Table Medigene Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Medigene Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Medigene Neoantigen Cancer Vaccine Product Portfolio

    • Table Genocea Company Details

    • Table Genocea Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genocea Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Genocea Neoantigen Cancer Vaccine Product Portfolio

    • Table Gritstone Oncology Company Details

    • Table Gritstone Oncology Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gritstone Oncology Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Gritstone Oncology Neoantigen Cancer Vaccine Product Portfolio

    • Table Nouscom Company Details

    • Table Nouscom Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nouscom Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Nouscom Neoantigen Cancer Vaccine Product Portfolio

    • Table Medimmune Company Details

    • Table Medimmune Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Medimmune Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Medimmune Neoantigen Cancer Vaccine Product Portfolio

    • Table Roche Company Details

    • Table Roche Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Roche Neoantigen Cancer Vaccine Product Portfolio

    • Table Geneos Therapeutics Company Details

    • Table Geneos Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Geneos Therapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Geneos Therapeutics Neoantigen Cancer Vaccine Product Portfolio

    • Table Neon Therapeutics Company Details

    • Table Neon Therapeutics Neoantigen Cancer Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neon Therapeutics Neoantigen Cancer Vaccine Main Business and Markets Served

    • Table Neon Therapeutics Neoantigen Cancer Vaccine Product Portfolio

    • Figure Global Personalized Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Off-the-shelf Neovaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Table North America Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure United States Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Germany Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure China Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Neoantigen Cancer Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Australia Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Neoantigen Cancer Vaccine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US